---

HOW TO USE THIS GUIDE

1. Start with Module theory - read and understand each module conceptually
2. Study the tables - they are high-yield for all exam formats
3. Memorize the one-liners - one sitting, repeat 3 times
4. Cover the answers and attempt fill-in-the-blanks out loud
5. Use the LAQ frameworks to write answers without seeing them

---

WHAT EACH SECTION COVERS

• 2L (minimum water), 150-200L (urban), 40L (rural India)
• 10-14 days (storage), 98-99% bacteria removal by filtration
• 70-80x (HOCl vs OCl⁻), 85 dB (safe noise), 25 dBA (bedroom)
• 4.3 million (indoor air pollution deaths), 34% (stroke)
• 1952 (London), 1804 (slow sand filter, Scotland)

---

PARK'S DEMOGRAPHY & FAMILY PLANNING - COMPLETE MASTER GUIDE

---

PART 1: DEMOGRAPHY - THEORY

---

MODULE 1: DEMOGRAPHY - DEFINITIONS & BASICS

---

MODULE 2: SOURCES OF DEMOGRAPHIC DATA

1. CENSUS

• India's first regular census: 1881
• Interval: every 10 years (decennial)
• Last census: March 2011
• Conducted at end of first quarter of first year of each decade (reason: most people are at home)
• Legal basis: Census Act of 1948
• Supreme officer: Census Commissioner for India
• Main drawback: full results not available quickly

• Total count of population
• Age and sex distribution
• Social and economic characteristics
• Base line for planning, action and research
• Basic data to compute vital statistical rates

2. REGISTRATION OF VITAL EVENTS

• Births, Deaths and Marriages Registration Act: 1873 (only voluntary registration)
• Registration of Births and Deaths Act, 1969 - made registration compulsory and uniform throughout India
• Civil Registration System (CRS) = current system

---

MODULE 3: VITAL STATISTICAL RATES & INDICES (HIGH YIELD)

MORTALITY INDICATORS

(a) Crude Death Rate (CDR)

• Deaths per 1000 population per year
• Fair indicator of comparative health of people
• Limitation: influenced by age-sex composition - NOT good for international comparison
• Also called: General Mortality Rate

CDR = (Total deaths in a year / Mid-year population) × 1000

---

(b) Infant Mortality Rate (IMR) ⭐ MOST IMPORTANT

• Deaths under 1 year of age per 1000 live births in the same year
• Most universally accepted indicator of health status - not just infants but whole population and socioeconomic conditions
• Sensitive indicator of: availability, utilization and effectiveness of health care, particularly perinatal care

IMR = (Deaths under 1 year / Total live births in same year) × 1000

---

(c) Neonatal Mortality Rate (NMR)

• Deaths in first 28 days (0-28 days) per 1000 live births
• Reflects maternal health, obstetric care, newborn care

---

(d) Post-neonatal Mortality Rate

• Deaths from 28 days to 1 year per 1000 live births

---

(e) Child Death Rate (1-4 years)

• Deaths at ages 1-4 years per 1000 children in that age group at mid-year
• Excludes infant mortality
• Related to: MCH services, nutrition, immunization coverage, environmental exposure
• Child mortality rate may be 25x higher in developing vs developed countries

---

(f) Under-5 Mortality Rate (U5MR)

• Deaths of children under 5 years per 1000 live births
• SDG indicator: reduce to at least as low as 25 per 1000 live births by 2030

---

(g) Maternal Mortality Ratio (MMR)

• Maternal deaths per 100,000 live births
• Maternal death = death of a woman while pregnant or within 42 days of termination of pregnancy, from any cause related to or aggravated by pregnancy or its management (not from accidental or incidental causes)
• NOT "rate" - technically a ratio

---

(h) Life Expectancy at Birth

• "Average number of years that will be lived by those born alive if current age-specific mortality rates persist"
• Good indicator of socio-economic development
• Adopted as global health indicator
• Life expectancy at age 1: excludes influence of infant mortality
• Life expectancy at age 5: excludes influence of child mortality

---

(i) Age-Specific Death Rate

• Deaths in a specific age group per 1000 population of that age group

---

FERTILITY INDICATORS

(a) Crude Birth Rate (CBR)

• Live births per 1000 population per year

CBR = (Total live births / Mid-year population) × 1000

---

(b) General Fertility Rate (GFR)

• Live births per 1000 women aged 15-49 years per year
• More refined than CBR as denominator is women of reproductive age

GFR = (Total live births / Mid-year female population aged 15-49) × 1000

---

(c) Total Fertility Rate (TFR)

• Average number of children a woman would have if she passes through her reproductive years (15-49) experiencing the current age-specific fertility rates
• Replacement level TFR = 2.1
• If TFR < 2.1 → population declining
• India's TFR: progressively declining

---

(d) Gross Reproduction Rate (GRR)

• Average number of female children born per woman passing through reproductive age group using current age-specific fertility rates
• TFR × proportion of female births

---

(e) Net Reproduction Rate (NRR)

• Average number of daughters born per woman, taking into account mortality
• NRR = 1.0 = exact replacement level
• NRR < 1 = population declining; NRR > 1 = population growing

---

OTHER IMPORTANT RATES

Sex Ratio

• Number of females per 1000 males (India definition)
• OR males per 1000 females (some countries)
• India 2011 Census: 943 females per 1000 males

Sex Ratio at Birth

• More males born than females worldwide
• Normal: ~105 males per 100 females at birth

Dependency Ratio

• (Population <15 years + population >65 years) / Population 15-64 years × 100
• Measures economic burden on working population

Natural Growth Rate

• = Birth rate - Death rate
• Positive = population growing
• Also called Rate of Natural Increase

---

MODULE 4: DEMOGRAPHIC CYCLE (DEMOGRAPHIC TRANSITION)

---

MODULE 5: POPULATION PYRAMID

• Graphical representation of age-sex distribution
• X-axis = population numbers; Y-axis = age groups; Left = males; Right = females
• Broad base pyramid = high birth rate, high death rate, young population (developing countries)
• Narrow base / rectangular = low birth rate, ageing population (developed countries)
• Inverted/narrow base = declining population (some European countries)

---

MODULE 6: INDIA'S POPULATION DATA

---

PART 2: FAMILY PLANNING - THEORY

---

MODULE 7: FAMILY PLANNING - DEFINITIONS & CONCEPTS

---

MODULE 8: CLASSIFICATION OF CONTRACEPTIVE METHODS

I. SPACING METHODS

• (a) Physical methods - condom, diaphragm, cervical cap
• (b) Chemical methods - spermicides (creams, gels, foam tablets)
• (c) Combined - condom + spermicide

• Oral contraceptive pills
• Injectables
• Implants

• Emergency contraception
• MTP (Medical Termination of Pregnancy)

• Natural family planning (NFP) methods: rhythm, LAM, withdrawal

---

II. TERMINAL METHODS (PERMANENT)

1. Male sterilization (vasectomy)
2. Female sterilization (tubectomy/tubal ligation)

---

MODULE 9: BARRIER METHODS

A. CONDOM (Nirodh)

• Most widely known barrier device for males
• India trade name: NIRODH (Sanskrit word = protection)
• Made of latex rubber
• Advantages:
  • Protects against STDs and HIV/AIDS
  • No systemic side effects
  • Readily available, low cost
  • No prescription needed
  • Can be used by the male partner
• Disadvantages:
  • Requires high motivation
  • Must be used consistently
  • May decrease sensitivity
  • Can break/slip
• Pearl index: ~3-14 (typical use)

B. DIAPHRAGM

• Cup-shaped rubber device worn by female; covers cervix
• Must be used with spermicide
• Inserted before intercourse; left in place 6-8 hours after
• Sizes: 50-105 mm; most common 65-80 mm
• Requires fitting by trained professional

C. CERVICAL CAP

• Smaller than diaphragm; fits over cervix only
• Used with spermicide
• Less effective than diaphragm in parous women

D. FEMALE CONDOM

• Polyurethane sheath inserted into vagina
• Protects against both pregnancy and STDs
• Advantage: female-controlled method

E. SPERMICIDES

• Chemical agents that immobilize/kill sperm
• Available as creams, jellies, foam tablets, suppositories
• Used alone or with barrier methods
• Effectiveness alone is low

---

MODULE 10: INTRA-UTERINE DEVICES (IUDs) ⭐

Classification of IUDs

• Previously: Cu-T-200B
• From 2002: Cu-T-380A (more effective)
• Short-term IUCD: Cu-IUCD-375 (5-year duration)

---

Mechanism of Action of IUDs

• Foreign-body reaction → cellular and biochemical changes in endometrium and uterine fluids
• Impairs viability of gametes → reduces chances of fertilization (NOT implantation - most current accepted view)

• Above + copper enhances cellular response in endometrium
• Affects enzymes in uterus
• Copper ions alter biochemical composition of cervical mucus → affects sperm motility, capacitation and survival

• Increases viscosity of cervical mucus → prevents sperm entering cervix
• Maintains high progesterone in endometrium → low oestrogen → endometrium unfavourable to implantation

---

Effectiveness

---

Duration of Use

• Inert IUDs (Lippes Loop): may be left in place indefinitely if no side effects
• Cu-T-200: 3-5 years
• Cu-T-380A: 10 years (highly effective)
• Levonorgestrel IUD: 5 years

---

Ideal Timing for IUD Insertion

• During menstruation or within 10 days of beginning of menstrual period
• Why: cervical canal diameter greater, uterus relaxed, myometrial contractions minimum, risk of pregnancy remote
• Can also be inserted: immediately postpartum (within first week after delivery = "immediate postpartum insertion") - higher risk of perforation
• Interval insertion: 6-8 weeks postpartum

---

Contraindications for IUD

• Suspected pregnancy
• Pelvic inflammatory disease (PID)
• Vaginal bleeding of undiagnosed aetiology
• Cancer of cervix, uterus or adnexa; pelvic tumours
• Previous ectopic pregnancy

• Anaemia
• Menorrhagia
• History of PID since last pregnancy
• Purulent cervical discharge
• Distortions of uterine cavity (congenital malformations, fibroids)
• Unmotivated person

---

Ideal IUD Candidate (PPFA criteria)

• Woman who has borne at least one child
• No history of pelvic disease
• Normal menstrual periods
• Willing to check the IUD tail
• Has access to follow-up
• Is in a monogamous relationship
• NOT recommended for nulliparous women or women with multiple partners (risk of PID and infertility)

---

MODULE 11: HORMONAL CONTRACEPTIVES

Oral Contraceptive Pills (OCP)

1. Combined OCP - oestrogen + progestogen
2. Progestogen-only pill (POP/Mini-pill) - progestogen alone
3. Emergency contraceptive pill (ECP) - high-dose progestogen or combined

1. Inhibits ovulation (primary mechanism - oestrogen component)
2. Alters cervical mucus (progestogen → thick mucus → prevents sperm entry)
3. Alters endometrium (makes it hostile to implantation)
4. Alters tubal motility

---

Injectable Contraceptives

• 150 mg IM injection every 3 months
• Highly effective, Pearl index <1
• Side effects: menstrual irregularities, weight gain, delay in return of fertility

• 200 mg IM every 2 months initially, then every 3 months

---

Emergency Contraceptive Pills (ECP)

• Must be taken within 72 hours (ideally within 12-24 hours) of unprotected intercourse
• Levonorgestrel 1.5 mg single dose OR 0.75 mg × 2 doses (12 hours apart)
• Also called: Morning-after pill, post-coital contraception
• Mechanism: mainly inhibits/delays ovulation; alters cervical mucus
• ASHA charges Rs. 2 for one ECP tablet (India programme)

---

Oral Contraceptive "Chhaya" (India)

• Centchroman = a non-hormonal, non-steroidal oral contraceptive
• Also called "Saheli"
• Weekly tablet (once weekly after initial loading dose)
• Made in India
• Added to contraceptive basket under National Programme

---

MODULE 12: NATURAL FAMILY PLANNING (NFP) METHODS

1. Rhythm Method (Calendar Method)

• Avoidance of intercourse during fertile period
• Fertile period: Ovulation occurs on 14th day before next menstruation; fertile window = 3 days before to 1 day after ovulation
• Formula: Short cycle - 18 = first fertile day; Long cycle - 11 = last fertile day
• Limitation: irregular cycles make this unreliable

2. Basal Body Temperature (BBT) Method

• Temperature drops slightly before ovulation, then rises 0.2-0.5°C after ovulation
• Avoid intercourse until temperature has been elevated for 3 consecutive days
• Limitation: must take temperature every morning before any activity

3. Cervical Mucus Method (Billings/Ovulation Method)

• Around ovulation: cervical mucus becomes copious, clear, slippery, "spinnbarkeit" (thread-like)
• After ovulation: mucus becomes thick, scanty, opaque
• Avoid intercourse during wet/slippery mucus days + 4 days after

4. Symptothermal Method

• Combination of BBT + cervical mucus + calendar method

5. Lactational Amenorrhoea Method (LAM)

• 3 conditions must ALL be met:
  1. Mother is fully/nearly fully breastfeeding
  2. Menses have not returned
  3. Baby is less than 6 months old
• Effectiveness: 98% if all 3 conditions met
• When any condition fails, another method must be used

6. Withdrawal (Coitus Interruptus)

• Male withdraws before ejaculation
• High failure rate (pre-ejaculatory fluid contains sperm)
• Least reliable NFP method

---

MODULE 13: STERILIZATION (TERMINAL METHODS)

A. FEMALE STERILIZATION (TUBECTOMY)

1. Laparoscopic sterilization (most common in India)
2. Minilap / mini-laparotomy
3. Conventional laparotomy
4. Hysteroscopic sterilization

• Ligation and excision (Pomeroy's method - most common)
• Ring application (Falope ring)
• Clip application (Filshie clip)
• Electrocoagulation

---

B. MALE STERILIZATION (VASECTOMY)

---

Comparison: Vasectomy vs Tubectomy

---

MODULE 14: MEASUREMENT OF CONTRACEPTIVE EFFECTIVENESS

Pearl Index

• Definition: Number of failures per 100 woman-years of exposure (HWY)
• Lower the Pearl index = more effective the method

Pearl Index = (Total accidental pregnancies / Total months of exposure) × 1200

• Factor 1200 = number of months in 100 years
• Months of exposure: deduct 10 months for full-term pregnancy, 4 months for abortion
• Minimum 600 months exposure needed before conclusions
• Limitation: failure rates decline with duration of use - Pearl index doesn't account for this

Life-Table Analysis

• Calculates failure rate for each month of use
• Cumulative failure rate can compare methods for any duration
• Overcomes limitation of Pearl index

---

MODULE 15: INDIA'S FAMILY PLANNING PROGRAMME

• 1952-61: Clinical approach (rhythm method, diaphragm)
• 1962-68: Extension education approach (IUCD introduced 1965)
• 1969-74: Cafeteria approach
• 1975-76: Target approach (controversial - vasectomy camps)
• 1977 onwards: Welfare approach (renamed Family Welfare Programme)
• 1996 onwards: Target-free approach (community needs assessment)
• Present: Reproductive and Child Health (RCH) Programme

---

Current Contraceptive Services (INDIA)

• ASHA delivers contraceptives at doorstep
• Launched in 233 pilot districts (July 11, 2011); expanded to entire country December 17, 2012
• ASHA charges: Rs. 1 for 3 condoms; Rs. 1 for OCP cycle; Rs. 2 for one ECP tablet

• ASHA counsels newly married couples → 2 years spacing after marriage
• Spacing of 3 years after birth of 1st child
• ASHA incentives: Rs. 500 for delaying first birth by 2 years; Rs. 500 for 3-year spacing; Rs. 1000 for permanent limiting method up to 2 children

• Launched in 146 high TFR districts
• Five-pronged strategy: assured services, capacity building, commodity security, promotional schemes, enabling environment

• MPA injection under "Antara Programme"
• Centchroman "Chhaya" (oral, non-hormonal)

• Provides compensation for deaths, complications, failures following sterilization

---

MODULE 16: UNMET NEED FOR FAMILY PLANNING

1. Unmet need for spacing - want to delay next birth but not using contraception
2. Unmet need for limiting - want no more children but not using contraception

---

PART 3: EXAM QUESTION GUIDE

---

LONG ANSWER QUESTIONS (LAQs)

LAQ 1: Demographic Cycle / Demographic Transition

1. Definition of demographic transition
2. 5 stages with birth rate, death rate, growth rate characteristics
3. Table format
4. Where India stands (Stage 3)
5. Implications for health planning

---

LAQ 2: Vital Statistics / Mortality Indicators

1. Definition of vital statistics
2. Sources: census + registration of vital events
3. Mortality indicators: CDR, IMR, NMR, Child death rate, MMR, life expectancy - all with formulas
4. Fertility indicators: CBR, GFR, TFR, GRR, NRR - with formulas
5. Importance of IMR as health indicator
6. India's registration system

---

LAQ 3: Contraceptive Methods

1. Definition of family planning
2. Ideal contraceptive - why none exists; cafeteria approach
3. Classification: spacing (barrier, IUD, hormonal, NFP, post-conceptional) vs terminal
4. Each method with mechanism, advantages, disadvantages
5. Pearl index table
6. Factors influencing choice

---

LAQ 4: IUD / Intra-Uterine Device

1. Definition + types (1st/2nd/3rd generation with examples)
2. Mechanism of action (foreign body reaction, copper, hormonal)
3. Effectiveness table
4. Ideal candidate (PPFA criteria)
5. Timing of insertion
6. Contraindications (absolute + relative)
7. Complications: pain, bleeding, expulsion, PID, ectopic pregnancy, perforation
8. Cu-T used in India's programme

---

LAQ 5: Family Planning Programme in India

1. India = first country to start national FP programme (1952)
2. Historical phases
3. Current approach: RMNCH+A / RCH
4. Services: HDC, ESB, Mission Parivar Vikas, Antara, Chhaya
5. Sterilization services + NFPIS
6. Unmet need concept
7. Achievements and challenges

---

SHORT NOTES (SNs)

SN 1: IMR (Infant Mortality Rate)

• Deaths under 1 year per 1000 live births
• Most universally accepted health indicator for whole population and socioeconomic conditions
• Sensitive indicator of perinatal care
• Includes neonatal (0-28 days) and post-neonatal (28 days - 1 year)

SN 2: Total Fertility Rate (TFR)

• Average children per woman if she lives through reproductive period with current age-specific fertility rates
• Replacement level = 2.1
• India's TFR declining; at replacement level in 44% of countries worldwide

SN 3: Pearl Index

• Number of failures per 100 woman-years of exposure
• Formula: (Pregnancies / Months of exposure) × 1200
• Lower = better contraceptive
• Limitation: doesn't account for declining failure rates over time

SN 4: Lactational Amenorrhoea Method (LAM)

• 3 conditions: exclusive breastfeeding + no menses + baby < 6 months old
• 98% effective if all 3 met
• When any condition fails → switch to another method immediately

SN 5: Demographic Transition

• Shift from high birth/death rates to low birth/death rates as country develops
• 5 stages: high stationary, early expanding, late expanding, low stationary, declining
• India = Stage 3

SN 6: Emergency Contraceptive Pill (ECP)

• Within 72 hours of unprotected intercourse
• Levonorgestrel 1.5 mg single dose
• Mainly inhibits/delays ovulation
• ASHA charges Rs. 2/tablet in India
• Also called morning-after pill / post-coital contraception

SN 7: Vasectomy vs Tubectomy (SN on differences)

• See differences table above

SN 8: Unmet Need for Family Planning

• Women who want to stop/delay childbearing but not using contraception
• Two types: spacing + limiting
• Important indicator for programme planning

---

DIFFERENCES (HIGH YIELD)

1. Census vs Registration of Vital Events

---

2. Crude Birth Rate vs Total Fertility Rate

---

3. GRR vs NRR

---

4. Spacing vs Terminal Contraceptive Methods

---

5. First, Second, Third Generation IUDs

---

6. IMR vs NMR vs Child Death Rate

---

ONE-LINERS

1. India was the first country in the world to start a national family planning programme (1952).
2. Census in India is conducted every 10 years; first regular census was in 1881.
3. Census Act of India = 1948; Registration of Births and Deaths Act = 1969.
4. Census Commissioner is the supreme officer directing the census.
5. IMR = deaths under 1 year per 1000 live births - most universally accepted health indicator.
6. Life expectancy at birth = global health indicator and indicator of socioeconomic development.
7. NMR reflects maternal health and obstetric care quality.
8. Replacement level TFR = 2.1.
9. NRR = 1.0 = exact replacement level of population.
10. Demographic transition is from high stationary to low stationary as countries develop.
11. India is in Stage 3 (Late expanding) of demographic transition.
12. Population pyramid with broad base = high birth rate, young population.
13. Sex ratio in India (2011) = 943 females per 1000 males.
14. Pearl index = failures per 100 woman-years of exposure.
15. Factor used in Pearl index formula = 1200 (months in 100 years).
16. Most effective non-permanent contraceptive = combined OCP (Pearl index 0.1-0.5).
17. Most effective IUD = Levonorgestrel IUD (Pearl index 0.2%).
18. IUD used in India's National Programme since 2002 = Cu-T-380A.
19. Lippes Loop can be left in place indefinitely if no side effects.
20. Most accepted mechanism of IUD = impairs fertilization (not implantation).
21. Copper ions impair sperm motility, capacitation and survival.
22. Hormone-releasing IUD increases cervical mucus viscosity (prevents sperm entry).
23. Ideal time for IUD insertion = during menstruation or within 10 days of beginning of period.
24. Absolute contraindication for IUD = PID, suspected pregnancy, previous ectopic pregnancy.
25. Ideal IUD candidate (PPFA) = at least one child, no PID history, monogamous.
26. LAM = 3 conditions: exclusive breastfeeding + no menses + baby <6 months.
27. LAM effectiveness = 98% if all 3 conditions met.
28. ECP must be taken within 72 hours of unprotected intercourse.
29. ASHA charge for ECP = Rs. 2 per tablet; OCP cycle = Rs. 1.
30. Vasectomy failure rate ~0.1%; tubectomy failure rate ~0.5%.
31. Vasectomy is NOT immediately effective - wait until azoospermia confirmed.
32. NSV = No-Scalpel Vasectomy - preferred, fewer complications.
33. MMR = maternal deaths per 100,000 live births (within 42 days of delivery).
34. Demographic transition fertility rate at replacement level in 44% of countries.
35. Centchroman "Chhaya" = India's non-hormonal, non-steroidal weekly oral contraceptive.
36. Antara Programme = DMPA injectable contraceptive programme in India.
37. Mission Parivar Vikas launched in 146 high-TFR districts.
38. HDC (Home Delivery of Contraceptives) expanded nationally on 17 December 2012.
39. NFPIS = National Family Planning Indemnity Scheme = compensation for sterilization deaths/complications.
40. Pearl index limitation = failure rates decline with duration of use (life-table analysis overcomes this).

---

FILL IN THE BLANKS

1. India's first regular census was taken in __________. (1881)
2. Censuses in India are conducted at __________ year intervals. (10)
3. The Census Act providing legal basis for census was passed in __________. (1948)
4. The Registration of Births and Deaths Act was passed in __________. (1969)
5. IMR is defined as deaths under __________ year per __________ live births. (1 year; 1000)
6. IMR is the most universally accepted indicator of __________. (health status)
7. Life expectancy at birth excludes the influence of __________ if calculated at age 1. (infant mortality)
8. Replacement level Total Fertility Rate = __________. (2.1)
9. When NRR = __________, population is at exact replacement level. (1.0)
10. The demographic cycle has __________ stages. (5)
11. India is currently in stage __________ of demographic transition. (3 / Late expanding)
12. Sex ratio in India as per 2011 census = __________ females per 1000 males. (943)
13. India was the __________ country in the world to start a national family planning programme. (first)
14. India's national family planning programme started in __________. (1952)
15. Pearl index = failures per __________ woman-years of exposure. (100)
16. The factor used in Pearl index formula = __________. (1200)
17. Pearl index limitation is overcome by using __________ analysis. (life-table)
18. Months deducted from exposure for full-term pregnancy in Pearl index = __________. (10 months)
19. Months deducted for abortion in Pearl index = __________. (4 months)
20. First generation IUDs are __________ (inert/copper/hormone). (inert)
21. Second generation IUDs are __________. (copper-bearing)
22. Third generation IUDs are __________. (hormone-releasing)
23. Lippes Loop is a __________ generation IUD. (first)
24. Cu-T-380A is a __________ generation IUD. (second)
25. The IUD used in India's national programme since 2002 = __________. (Cu-T-380A)
26. Cu-T-380A can be used for __________ years. (10)
27. Levonorgestrel IUD has a pregnancy rate of __________ per year. (0.2%)
28. Most accepted mechanism of IUD action = impairs __________ (not implantation). (fertilization)
29. Copper ions affect sperm __________, __________, and __________. (motility, capacitation, survival)
30. Best time for IUD insertion = during __________ or within __________ days of its beginning. (menstruation; 10)
31. Ideal IUD candidate should have borne at least __________ child. (one)
32. IUDs are theoretically contraindicated in adolescents due to risk of __________ and __________. (PID; secondary sterility)
33. The 3 conditions for LAM are: exclusive breastfeeding + __________ + baby < __________. (no menses; 6 months)
34. Effectiveness of LAM when all conditions met = __________ %. (98)
35. ECP must be taken within __________ hours of unprotected intercourse. (72)
36. ASHA charges Rs. __________ for one ECP tablet. (2)
37. DMPA injection under "Antara Programme" is given every __________ months. (3)
38. "Chhaya" is __________ (name of drug) and is taken __________. (centchroman; weekly)
39. Vasectomy failure rate ≈ _______%; Tubectomy failure rate ≈ ________%. (0.1%; 0.5%)
40. Vasectomy is confirmed effective when __________ is confirmed. (azoospermia)
41. NSV stands for __________. (No-Scalpel Vasectomy)
42. MMR = maternal deaths per __________ live births. (100,000)
43. Maternal death = death within __________ days of termination of pregnancy. (42)
44. Mission Parivar Vikas was launched in __________ high-TFR districts. (146)
45. NFPIS stands for __________. (National Family Planning Indemnity Scheme)

---

QUICK MEMORY AIDS

Demographic Transition = HELLD

• High stationary (Stage 1)
• Early expanding (Stage 2)
• Late expanding (Stage 3) ← India here
• Low stationary (Stage 4)
• Declining (Stage 5)

IMR vs NMR vs Child DR = UND

• Under 1 year = IMR
• Neonatal (0-28 days) = NMR
• 1-4 years = Child death rate

IUD generations = IUDs Go Hormonal

• Inert = 1st generation
• Uncovered copper = 2nd generation
• Directly hormonal = 3rd generation

LAM = BMA (all 3 for 98%)

• Breastfeeding exclusively
• Menses absent
• Age of baby < 6 months

Pearl Index Key Numbers

• 0.1 = vasectomy / OCP (best)
• 0.5 = tubectomy
• 3 = condom / Lippes Loop
• 85 = no method

Contraceptive Classification = BIHPN (Spacing) + TS (Terminal)

• Barrier (physical, chemical, combined)
• IUD
• Hormonal (pill, injection, implant)
• Post-conceptional
• Natural (NFP, LAM, rhythm, BBT)
• Tubectomy + Sterilization (vasectomy)

---

---

PARK'S HOSPITAL/BIO-MEDICAL WASTE MANAGEMENT - COMPLETE MASTER GUIDE

---

PART 1: THEORY (Learn & Understand)

---

MODULE 1: DEFINITION & BASICS

Definition of Bio-Medical Waste (BMW)

"Bio-medical waste means any waste which is generated during the diagnosis, treatment or immunization of human beings or animals, or in research activities pertaining thereto, or in the production or testing of biologicals."

Key Proportions (MEMORIZE)

---

MODULE 2: SOURCES OF HEALTH-CARE WASTE

• Government & private hospitals
• Nursing homes, physician's/dentist's offices, dispensaries
• Primary Health Centres
• Medical research and training establishments
• Mortuaries
• Blood banks and collection centres
• Animal houses, slaughter houses
• Laboratories, research organizations
• Vaccinating centres
• Biotechnology institutions/production units

---

MODULE 3: HEALTH-CARE WASTE GENERATION & COMPOSITION

Average Distribution (WHO estimates for developing countries):

Factors affecting waste generation:

• Established waste management methods
• Type of health-care establishment
• Hospital specializations
• Proportion of reusable items
• Proportion of day-care patients

---

MODULE 4: HEALTH HAZARDS OF HEALTH-CARE WASTE

1. Hazards from Infectious Waste and Sharps

• Health-care workers
• Patients
• Visitors to health-care establishments
• Workers in support services (laundry, waste disposal, transport)
• General public

• HIV (risk per needlestick ~0.3%)
• Hepatitis B (risk per needlestick ~30%) - highest risk
• Hepatitis C (risk ~3%)
• Other bloodborne pathogens

• Gastroenteric infections - Enteric fever, dysentery, cholera, Hep A
• Respiratory tract infections - TB, measles, SARS
• Genital tract infections - Gonorrhoea, syphilis
• Skin and eye infections
• Other infections - anthrax, brucellosis

2. Hazards from Chemical and Pharmaceutical Waste

• Skin/mucous membrane burns from chemicals
• Damage to CNS, cardiovascular, reproductive systems
• Cytotoxic drugs → genotoxicity, mutagenicity, carcinogenicity

3. Hazards from Radioactive Waste

• Headache, dizziness, nausea
• Radiation burns
• Increased risk of cancer
• Genetic mutations

---

MODULE 5: CLASSIFICATION & COLOUR CODING (BMW RULES 2016) ⭐⭐

COLOUR-CODED BAG/CONTAINER SYSTEM:

*Deep burial: Only in rural areas or areas where incinerators/common BMW facilities are not available.

Memory Aid for Colour Coding:

• YELLOW = Highly hazardous (incinerate or deep bury) = Human/animal body parts, soiled waste, drugs
• RED = Recyclable contaminated = Tubings, syringes without needles, gloves, blood bags
• WHITE = Sharps = Needles, scalpels, blades
• BLUE = Glass = Vials, ampoules, glass

---

MODULE 6: TREATMENT METHODS

I. INCINERATION ⭐

• High temperature dry oxidation process
• Reduces organic/combustible waste to inorganic incombustible matter
• Significant reduction in waste volume and weight
• Method of choice for most hazardous health-care wastes

• Low heating value: >2,000 kcal/kg (single-chamber) or >3,500 kcal/kg (pyrolytic double-chamber)
• Combustible matter: above 60%
• Non-combustible solids: below 5%
• Non-combustible fines: below 20%
• Moisture content: below 30%

• Pressurized gas containers
• Large amounts of reactive chemical wastes
• Silver salts and photographic/radiographic wastes
• Halogenated plastics (PVC)
• Waste with high mercury or cadmium content (broken thermometers, used batteries, lead-lined panels)
• Sealed ampules or ampules containing heavy metals

1. Double-chamber pyrolytic incinerators - especially designed for infectious health-care waste (best)
2. Single-chamber furnaces with static grate - only when pyrolytic not affordable
3. Rotary kilns - high temperatures; decompose genotoxic substances and heat-resistant chemicals

---

II. CHEMICAL DISINFECTION

• Uses chemicals (e.g., bleach, formaldehyde) to kill microorganisms
• Used for: liquid waste, some solid infectious waste
• Not suitable for: cytotoxic waste, some chemical waste

---

III. AUTOCLAVING (STEAM STERILIZATION)

• Steam under pressure (121°C, 15 psi, 15-30 minutes)
• Used for: red bag waste (contaminated recyclable items), sharps (white)
• Kills vegetative organisms and spores
• Advantages: no toxic emissions, well-established technology
• Limitations: does not reduce volume, not suitable for anatomical waste, chemical waste, cytotoxic waste

---

IV. MICROWAVING

• Uses microwave radiation to heat moisture in waste → kills microorganisms
• Used for: infectious waste including sharps
• Must be pre-shredded and humidified
• Does not reduce volume unless combined with shredding

---

V. HYDROCLAVING

• Steam sterilization combined with mechanical mixing of waste
• Effective for infectious waste

---

VI. DEEP BURIAL

• Only in rural areas or areas without incineration/common BMW facilities
• Pit dimensions: at least 2 metres deep, lined with lime
• Covered with earth so animals cannot access
• Site: away from water bodies, minimum 25 metres from well/water source
• Not recommended for urban areas

---

VII. PLASMA PYROLYSIS

• Thermal process using ionized gas (plasma) at very high temperatures
• Suitable for: anatomical waste, cytotoxic drugs (>1200°C)

---

VIII. ENCAPSULATION

• Filling sharps/waste in containers with immobilizing material (concrete, bituminous sand, plastic foam)
• Used for certain chemical and pharmaceutical waste

---

MODULE 7: SEGREGATION & HANDLING

Principle of Segregation

Containers/Bags Requirements:

• Must be colour-coded as per schedule
• Labels must be non-washable and prominently visible
• Sharps disposed in puncture-proof, leak-proof containers (white translucent)
• Yellow bags: non-chlorinated plastic (to prevent dioxin release during incineration)
• COVID-19 addition: Foot-operated lids in colour-coded bins (to avoid contact)

Transportation:

• Within facility: designated trolleys/carts
• To common BMW treatment facility (CBWTF): special vehicles with GPS tracking
• Manifold system for tracking waste movement
• Never transported with general waste

---

MODULE 8: IMPORTANT LEGISLATIONS (INDIA)

Key Changes in 2016 Rules over 1998 Rules:

• Colour coding simplified from 10 to 4 categories (Yellow, Red, White, Blue)
• Added plasma pyrolysis and hydroclaving as treatment options
• Mandatory training for health-care workers
• GPS tracking of waste transport vehicles
• Bar-coding of waste bags
• Common Bio-Medical Waste Treatment Facilities (CBWTFs) emphasized
• Increased penalty for violations

---

MODULE 9: ROLES & RESPONSIBILITIES

Occupier (Hospital/Health-care Facility):

• Ensure proper segregation, collection, storage, transport, treatment, disposal
• Provide training to all healthcare workers
• Must have a Bio-Medical Waste Management Committee
• Annual report to Pollution Control Board

Common Bio-Medical Waste Treatment Facility (CBWTF):

• Centralized facility serving multiple health-care establishments
• Provides collection, treatment, and disposal services
• Authorized by State Pollution Control Board

Pollution Control Boards:

• CPCB (Central Pollution Control Board) - overall monitoring
• SPCB (State Pollution Control Board) - authorization, monitoring at state level

---

MODULE 10: NEEDLE-STICK INJURY PREVENTION & MANAGEMENT

Prevention:

1. Never recap needles (recapping = most common cause of needlestick injuries)
2. Use safety-engineered devices (retractable needles, needleless systems)
3. Proper sharps containers at point of use
4. Personal Protective Equipment (PPE)
5. Training and education

Post-Exposure Prophylaxis (PEP):

• For HIV: Start PEP within 72 hours (ideally within 2 hours)
• For Hepatitis B: Hepatitis B immunoglobulin + vaccine
• Report all needlestick injuries

---

MODULE 11: TYPES OF HOSPITAL WASTE - OLD CLASSIFICATION (for context)

1. General waste - non-hazardous; administrative, housekeeping
2. Pathological waste - tissues, organs, body fluids, blood
3. Radioactive waste - radiotherapy, diagnostic isotopes
4. Chemical waste - disinfectants, solvents, laboratory chemicals
5. Infectious waste - cultures, waste from infectious disease wards, sharps
6. Sharps - needles, blades, broken glass
7. Pharmaceutical waste - expired drugs, vaccines
8. Pressurized containers - gas cylinders, aerosol cans
9. Genotoxic/cytotoxic waste - cytotoxic drugs, body fluids with cytotoxics

---

PART 2: EXAM QUESTION GUIDE

---

LONG ANSWER QUESTIONS (LAQs)

LAQ 1: Bio-Medical Waste Management

1. Definition (BMW Rules 1998 & 2016)
2. Key proportion: 75-90% general, 10-25% hazardous
3. Sources of health-care waste (list)
4. Waste composition (80% general, 15% pathological, 1% sharps, 3% chemical)
5. Colour-coding table: Yellow, Red, White, Blue - waste type + treatment
6. Treatment methods: Incineration (most important), autoclaving, chemical disinfection, microwaving, deep burial
7. Incineration details: suitable waste characteristics, types NOT to incinerate, 3 types of incinerators
8. Legislation: 1998 Rules → 2016 Rules
9. Health hazards (infectious, chemical, radioactive)

---

LAQ 2: Health Hazards of Hospital Waste

1. Who is at risk (5 groups)
2. Hazards from sharps/infectious waste: HIV, HBV, HCV (risk percentages)
3. Infections from waste: gastroenteric, respiratory, genital, skin/eye
4. Hazards from chemical waste: burns, organ damage
5. Cytotoxic hazards: genotoxicity, carcinogenicity
6. Radioactive hazards
7. Prevention: segregation, colour coding, PPE, safe disposal, training, legislation

---

LAQ 3: Incineration

1. Definition: high temperature dry oxidation
2. Suitable waste characteristics (5 criteria with values)
3. Waste NOT suitable for incineration (6 types)
4. Types of incinerators: double-chamber pyrolytic, single-chamber static grate, rotary kilns
5. Advantages: reduces volume significantly, destroys pathogens
6. Disadvantages: expensive, air pollution, toxic emissions (dioxins from PVC)

---

SHORT NOTES (SNs)

SN 1: Colour Coding of Bio-Medical Waste

SN 2: Needle-Stick Injury

• Most common occupational hazard in healthcare workers
• Risk: HBV 30%, HCV 3%, HIV 0.3%
• Prevention: no recapping, safety devices, sharps containers at point of use
• PEP for HIV: within 72 hours
• Most common cause: recapping of needles

SN 3: Deep Burial

• Only in rural areas or without incineration facilities
• Pit at least 2 metres deep
• Lined with lime
• 25 metres away from water source
• Covered with earth; animal-proof

SN 4: Autoclaving

• Steam sterilization: 121°C, 15 psi, 15-30 minutes
• Used for: red bag waste, white bag sharps
• Does not reduce volume
• Not suitable for anatomical, cytotoxic, or radioactive waste

SN 5: Segregation of BMW

• Separation at point of generation
• Must use colour-coded bags/containers
• Hazardous waste NEVER mixed with general waste
• Yellow bags must be non-chlorinated plastic
• Labels must be non-washable and prominently visible

SN 6: Bio-Medical Waste Rules 2016

• Replaced 1998 rules; came into force 28 March 2016
• Simplified to 4 colour categories (from 10)
• Added plasma pyrolysis, hydroclaving
• GPS tracking of transport vehicles
• Bar-coding of bags
• Mandatory training emphasized

---

DIFFERENCES (HIGH YIELD)

1. BMW Rules 1998 vs BMW Rules 2016

---

2. Incineration vs Autoclaving

---

3. General Waste vs Hazardous Waste

---

4. Yellow vs Red Bag Waste

---

ONE-LINERS (Exam Ready)

1. BMW = waste generated during diagnosis, treatment, immunization, research, or testing of biologicals.
2. 75-90% of health-care waste is general/non-risk; 10-25% is hazardous.
3. BMW Rules 1998 came into force on 28 July 1998.
4. BMW Management Rules 2016 came into force on 28 March 2016.
5. Current law for BMW in India = Bio-Medical Waste Management Rules, 2016.
6. 4 colour categories under 2016 Rules: Yellow, Red, White (translucent), Blue.
7. Yellow bag = anatomical waste, soiled waste, expired medicines → incineration/deep burial.
8. Red bag = contaminated recyclables (syringes WITHOUT needles, tubing) → autoclaving + recycling.
9. White (translucent) = sharps (needles, blades, scalpels) → autoclave/dry heat + shred + metal recycler.
10. Blue = glass (vials, ampoules) → chemical disinfection + recycling.
11. Yellow bags must be non-chlorinated plastic (prevents dioxin release during incineration).
12. Labels on BMW bags must be non-washable and prominently visible.
13. Incineration = high temperature dry oxidation process.
14. Incineration suitable if moisture content below 30% and combustible matter above 60%.
15. PVC (halogenated plastics) must NOT be incinerated.
16. Cytotoxic drugs require incineration at >1200°C.
17. Three types of incinerators: double-chamber pyrolytic, single-chamber static grate, rotary kilns.
18. Autoclaving = steam sterilization at 121°C, 15 psi, 15-30 minutes.
19. Deep burial pit must be at least 2 metres deep, minimum 25 metres from water source.
20. Deep burial is only for rural areas without incineration facilities.
21. Most common cause of needlestick injury = recapping of needles.
22. Risk per needlestick: HBV = 30% (highest), HCV = 3%, HIV = 0.3% (lowest).
23. HIV PEP must start within 72 hours of needlestick.
24. Segregation must happen at the point of generation.
25. Hazardous waste must NEVER be mixed with general waste.
26. Average hospital waste composition: 80% general, 15% pathological/infectious, 1% sharps.
27. Plasma pyrolysis was added to BMW rules in 2016 (not in 1998).
28. GPS tracking of transport vehicles = mandatory under 2016 Rules.
29. Common Bio-Medical Waste Treatment Facility = CBWTF.
30. Slaughter houses and biotechnology institutions are also covered under BMW Rules.
31. COVID-19 addition: foot-operated lids in colour-coded bins to avoid contact.
32. Post-COVID: all waste handlers must follow hand washing, gloves, mask, PPE.
33. Genotoxic/cytotoxic waste → risk of carcinogenicity, mutagenicity, teratogenicity.
34. Encapsulation = filling sharps/waste in containers with immobilizing material (concrete, bituminous sand).
35. Radioactive waste causes: headache, nausea, burns, cancer, genetic mutations.

---

FILL IN THE BLANKS

1. BMW = waste generated during __________, __________, or __________ of human beings or animals. (diagnosis; treatment; immunization)
2. __________ to __________ per cent of health-care waste is non-risk/general waste. (75; 90)
3. __________ to __________ per cent of health-care waste is hazardous. (10; 25)
4. BMW (Management and Handling) Rules 1998 came into force on __________. (28 July 1998)
5. BMW Management Rules 2016 came into force on __________. (28 March 2016)
6. Under BMW Rules 2016, there are __________ colour categories. (4)
7. Yellow bags must be made of __________ plastic. (non-chlorinated)
8. Yellow bag waste is treated by __________ or plasma pyrolysis or __________. (incineration; deep burial)
9. Red bag waste contains contaminated __________ items and is treated by __________. (recyclable; autoclaving)
10. White (translucent) bag is used for __________ waste. (sharps)
11. Blue bag is used for __________ waste. (glass)
12. Incineration is a __________ temperature __________ oxidation process. (high; dry)
13. For incineration, moisture content should be below __________ %. (30)
14. For incineration, combustible matter should be above __________ %. (60)
15. __________ plastics such as PVC should NOT be incinerated. (Halogenated)
16. Cytotoxic drugs require incineration at temperature > __________°C. (1200)
17. Three types of incinerators: __________, single-chamber, and __________. (double-chamber pyrolytic; rotary kilns)
18. Autoclaving is done at __________°C, __________ psi, for __________ minutes. (121; 15; 15-30)
19. Deep burial pit must be at least __________ metres deep. (2)
20. Deep burial site must be minimum __________ metres from well/water source. (25)
21. Most common cause of needlestick injury = __________ of needles. (recapping)
22. Risk of HIV transmission per needlestick = __________ %. (0.3)
23. Risk of HBV transmission per needlestick = __________ % (highest). (30)
24. HIV PEP must start within __________ hours of needlestick. (72)
25. Segregation of BMW must happen at the __________ of generation. (point)
26. Average hospital waste: __________ % is general waste; __________ % is sharps. (80; 1)
27. CBWTF stands for __________. (Common Bio-Medical Waste Treatment Facility)
28. Labels on BMW containers must be __________ and prominently visible. (non-washable)
29. COVID-19 addition to BMW handling = __________ operated lids on bins. (foot)
30. __________ is a thermal process using ionized gas at very high temperatures. (Plasma pyrolysis)

---

QUICK MEMORY AIDS

4 COLOURS = YAWB (Yellow And White Blue)

• Yellow = Yucky/anatomical/soiled + drugs → Incinerate/deep bury
• Red = Recyclable (contaminated tubings/syringes) → Autoclave + recycle
• White = sharps (Weapons) → Autoclave + shred + metal recycle
• Blue = Broken glass → Disinfect + recycle

BMW Rules dates = 1998 (first) → 2016 (current)

• 98 → force 28 July 1998
• 2016 → force 28 March 2016

Waste NOT for Incineration = P-RSHMA (3 seconds trick)

• Pressurized gas containers
• Radiographic/silver salt wastes
• Sealed/heavy metal ampules
• Halogenated plastics (PVC)
• Mercury/cadmium items (thermometers, batteries)
• Ampules with heavy metals

Needlestick Risk = "Thirty, Three, Point-three"

• HBV = 30%
• HCV = 3%
• HIV = 0.3%

Autoclaving = 121-15-15

• 121°C, 15 psi, 15 minutes

Incineration Characteristics = combustible > 60%, moisture < 30%, non-combustibles < 5%

---

1. ✅ Environmental Health
2. ✅ Demography & Family Planning
3. ✅ Hospital/Bio-Medical Waste Management

• Epidemiology (concepts, study designs, measures of disease)
• Communicable disease control (chain of infection, surveillance)
• Nutrition (PEM, deficiency diseases, national programmes)
• Maternal & Child Health (MCH services, RMNCH+A)
• Health Planning & Administration (PHC, Bhore Committee, NHP)
• Immunization (vaccines, cold chain, UIP)
• Occupational Health (detailed)
• Social Medicine & Health concepts

---

PARK'S SCREENING FOR DISEASE - COMPLETE MASTER GUIDE

---

PART 1: THEORY (Learn & Understand)

---

MODULE 1: DEFINITIONS

Screening (Classic definition)

"The search for unrecognized disease or defect by means of rapidly applied tests, examinations or other procedures in apparently healthy individuals."

How screening differs from periodic health examination:

1. Capable of wide application
2. Relatively inexpensive
3. Requires little physician-time (physician not needed to administer - only to interpret)

---

Screening vs Case-Finding vs Diagnostic Tests

---

MODULE 2: LEAD TIME

• Screening only benefits if lead time translates into improved outcome
• No benefit if disease is equally fatal whether detected early or late
• Screening should target conditions where a latent or asymptomatic stage exists, and early treatment changes prognosis

---

MODULE 3: USES OF SCREENING (4 main uses)

a. Case Detection (= Prescriptive Screening)

• Presumptive identification of unrecognized disease which does not arise from patient's request
• People screened primarily for their own benefit
• Examples: neonatal PKU screening, bacteriuria in pregnancy, breast cancer, cervical cancer, diabetes, iron deficiency anaemia, pulmonary TB, haemolytic disease of newborn
• Medical personnel must ensure appropriate treatment is started early

b. Control of Disease (= Prospective Screening)

• People examined for the benefit of others
• Examples: screening immigrants for TB/syphilis; screening food handlers for enteric disease carriers; antenatal screening for syphilis

c. Research

• To determine prevalence of a condition to understand its natural history
• Example: surveys to measure prevalence of diabetes, hypertension

d. Evaluation

• To evaluate effectiveness of a control programme
• Examples: surveys to evaluate immunization programmes, dietary surveys to evaluate nutritional programmes

---

MODULE 4: TYPES OF SCREENING

a. Mass Screening

• Screening of the whole population or a large sub-group (e.g., all adults)
• Offered to all, irrespective of individual risk (e.g., tuberculosis)
• NOT a useful preventive measure unless backed up by suitable treatment
• Indiscriminate mass screening = not justified unless treatment reduces duration or alters outcome

b. High-Risk (Selective) Screening ⭐

• Applied selectively to high-risk groups defined by epidemiological research
• Most productive type of screening
• Examples:
  • Cancer cervix → screen lower social groups (higher incidence there)
  • Diabetes/hypertension/breast cancer → screen family members of cases
  • CHD → screen those with elevated serum cholesterol (risk factor screening)
• Extends to screening for risk factors (e.g., serum cholesterol for CHD, hypertension)
• Advantages: economical use of resources; higher yield

c. Multiphasic Screening

• Application of two or more screening tests in combination to a large number of people at one time
• May include: health questionnaire, clinical examination, blood/urine tests, lung function, audiometry, visual acuity
• Evidence: Randomized controlled studies in UK and USA showed no benefit in reducing morbidity and mortality
• Increased cost without observable benefit
• Most tests not validated
• Conclusion: Utility of multiphasic screening is doubtful

---

MODULE 5: CRITERIA FOR SCREENING ⭐⭐ (Most exam-tested)

---

A. Criteria Related to DISEASE (9 criteria)

1. The condition should be an important health problem (high prevalence)
2. There should be a recognizable latent or early asymptomatic stage
3. The natural history of the condition should be adequately understood (including at what stage it becomes irreversible)
4. There is a test that can detect disease prior to onset of signs and symptoms
5. Facilities available for confirmation of diagnosis
6. There is an effective treatment
7. There should be an agreed-on policy about whom to treat (e.g., borderline diabetes, lower ranges of blood pressure)
8. Evidence that early detection and treatment reduces morbidity and mortality
9. Expected benefits exceed the risks and costs

---

B. Criteria Related to SCREENING TEST (6 criteria)

1. Acceptability - acceptable to the target population (painful/embarrassing tests fail)
2. Repeatability (= reliability, precision, reproducibility)
3. Validity (sensitivity + specificity)
4. Yield
5. Simplicity - can be administered by technicians, not requiring physicians
6. Safety, rapidity, ease of administration, low cost

---

MODULE 6: REPEATABILITY (RELIABILITY)

• Also called: reliability, precision, reproducibility

1. Observer variation
2. Biological (subject) variation
3. Errors relating to technical methods

Observer Variation (Two Types):

• Due to: fatigue, subjectivity, changes in personal criteria

• More common and more serious than intra-observer variation

Reducing Observer Variation:

• Standardization of methods
• Training of observers
• Use of automated devices
• Blinding

---

MODULE 7: VALIDITY ⭐⭐⭐ (MOST IMPORTANT - ALWAYS ASKED)

1. Sensitivity
2. Specificity

---

THE 2×2 TABLE (Memorize this absolutely)

                    DISEASE
                 Present   Absent
SCREENING   +ve  |  a    |   b  |  a+b
TEST        -ve  |  c    |   d  |  c+d
                  a+c     b+d    a+b+c+d

• a = True Positives (TP) - diseased AND test positive
• b = False Positives (FP) - not diseased but test positive
• c = False Negatives (FN) - diseased but test negative
• d = True Negatives (TN) - not diseased AND test negative

---

SENSITIVITY

"Ability of a test to identify correctly all those who have the disease" = True Positive Rate

• 90% sensitivity = 90% of diseased people give true-positive result; 10% give false-negative
• High sensitivity → few false negatives
• Used when: consequences of missing a case are serious (e.g., HIV, cancer)
• A sensitive test rules out disease if negative → "SnOut" - Sensitive test, Negative result = rules OUT disease

---

SPECIFICITY

"Ability of a test to identify correctly those who do NOT have the disease" = True Negative Rate

• 90% specificity = 90% of non-diseased people give true-negative result; 10% give false-positive
• High specificity → few false positives
• Used when: false positives lead to harmful/expensive further testing
• A specific test rules in disease if positive → "SpIn" - Specific test, Positive result = rules IN disease

---

FALSE NEGATIVE

False negative = "False reassurance" - diseased patient told they do NOT have disease

• Patient may ignore symptoms, postpone treatment → detrimental if serious disease
• Lower the sensitivity → larger the number of false negatives

---

FALSE POSITIVE

False positive = normal healthy person told they HAVE disease

• Subjected to further tests → inconvenience, discomfort, anxiety, expense
• Burdens diagnostic facilities
• Brings discredit to screening programmes
• Higher specificity → fewer false positives

No screening test is 100% sensitive AND 100% specific.

---

PREDICTIVE VALUE ⭐

Probability that a patient with a positive test actually has the disease

Probability that a patient with a negative test truly does NOT have the disease

---

KEY RELATIONSHIP: Predictive Value & Prevalence ⭐⭐

The more prevalent the disease, the higher the predictive value of a positive test. The predictive value of a positive result FALLS as disease prevalence DECLINES.

• Screening is more useful in high-prevalence populations
• Screening populations with low prevalence → many false positives → low PPV
• A test with same sensitivity/specificity performs BETTER in high-prevalence settings

---

WORKED EXAMPLE (Park's own example):

• a (TP) = 40, b (FP) = 20, c (FN) = 100, d (TN) = 9,840

---

MODULE 8: YIELD

"The amount of previously unrecognized disease diagnosed as a result of screening effort"

1. Sensitivity of the test
2. Specificity of the test
3. Prevalence of the disease (most important)
4. Participation rate of individuals

• Target high-risk groups (high prevalence)
• Example: restrict diabetes screening to persons over 40 years → increases yield

---

MODULE 9: SENSITIVITY vs SPECIFICITY TRADE-OFF

• Changing the cut-off point (criterion of positivity) changes both
• Lowering the cut-off → sensitivity ↑, specificity ↓ (more true positives but also more false positives)
• Raising the cut-off → specificity ↑, sensitivity ↓

---

MODULE 10: COMBINATION OF TESTS

• First test: RPR (high sensitivity but false positives)
• Second test: FTA-ABS (more specific, confirms positive RPR)

1. Parallel testing (simultaneous) → run both tests at same time → increases sensitivity; used in emergencies; more false positives
2. Serial/Sequential testing → test 2 only done if test 1 positive → increases specificity; reduces false positives; takes more time

---

MODULE 11: CRITERIA FOR A GOOD SCREENING TEST (Summary)

---

MODULE 12: EVALUATION OF SCREENING PROGRAMMES

1. Randomized Controlled Trial (RCT) - ideal; one group screened, control not; but for low-frequency, long-latency diseases (cancer) → requires tens of thousands of people for 10-20 years → cost and logistics prohibitive
2. Uncontrolled trials - compare survival of screened vs non-screened
3. Other methods - case-control studies, comparison of trends between areas with different screening coverage

---

MODULE 13: SOME SCREENING TESTS BY AGE GROUP

---

PART 2: EXAM QUESTION GUIDE

---

LONG ANSWER QUESTIONS (LAQs)

LAQ 1: Screening for Disease

1. Definition (WHO/classic)
2. Lead time concept
3. Uses (4): case detection, disease control, research, evaluation
4. Types: mass, high-risk/selective, multiphasic (with limitations of each)
5. Criteria for screening: disease (9 points) + test (acceptability, repeatability, validity, yield, simplicity, safety)
6. Validity: sensitivity, specificity, PPV, NPV with formulas and 2×2 table
7. False negative + false positive - definitions, consequences
8. Yield and factors affecting it
9. Predictive value and its relationship with prevalence
10. Evaluation methods: RCT, uncontrolled trials

---

LAQ 2: Sensitivity, Specificity, Predictive Value

1. 2×2 table construction (a, b, c, d)
2. Sensitivity = a/(a+c) × 100 - definition, formula, example, implication
3. Specificity = d/(b+d) × 100 - definition, formula, example, implication
4. False negative rate + consequences
5. False positive rate + consequences
6. PPV = a/(a+b) × 100
7. NPV = d/(c+d) × 100
8. Relationship between PPV and prevalence (critical concept)
9. Trade-off between sensitivity and specificity
10. SnOut and SpIn mnemonics

---

LAQ 3: Criteria for Screening

1. Importance of criteria (ethical, scientific, financial justification)
2. Disease criteria (9 points in full)
3. Test criteria (acceptability, repeatability, validity, yield, simplicity, safety, cost)
4. Examples for each criterion

---

SHORT NOTES (SNs)

SN 1: Sensitivity and Specificity

• Sensitivity = ability to detect true positives → a/(a+c) × 100
• Specificity = ability to detect true negatives → d/(b+d) × 100
• High sensitivity → few false negatives; high specificity → few false positives
• No test is 100% sensitive AND specific
• Inverse relationship: as one rises, the other falls

SN 2: Predictive Value

• PPV = a/(a+b) × 100 = probability positive test = truly diseased
• NPV = d/(c+d) × 100 = probability negative test = truly not diseased
• PPV rises with prevalence - most important concept
• Same test has different PPV in high vs low prevalence population

SN 3: Lead Time

• Period between screening detection and clinical detection of disease
• Represents potential benefit from screening
• Screening only beneficial if lead time → improved prognosis
• No point screening diseases without a latent/asymptomatic stage

SN 4: Multiphasic Screening

• Two or more tests applied simultaneously to large numbers
• Evidence shows NO reduction in morbidity/mortality (RCTs in UK and USA)
• Increased cost without observable benefit
• Most tests not validated
• Utility is doubtful

SN 5: High-Risk (Selective) Screening

• Most productive type; targets high-risk groups from epidemiological research
• Higher yield; economical use of resources
• Extends to screening for risk factors (cholesterol for CHD)
• Example: cancer cervix in lower socioeconomic groups

SN 6: False Negatives and False Positives

• False Negative = diseased person told NOT diseased = "false reassurance" → dangerous
• False Positive = healthy person told diseased → anxiety, further testing, discredits screening
• Lower sensitivity → more false negatives
• Lower specificity → more false positives

SN 7: Observer Variation

• Intra-observer = same observer, different times
• Inter-observer = between two or more observers (more common, more serious)
• Caused by: fatigue, subjectivity, technical errors
• Reduces repeatability of a test

---

DIFFERENCES (HIGH YIELD)

1. Screening Test vs Diagnostic Test

---

2. Sensitivity vs Specificity

---

3. Intra-observer vs Inter-observer Variation

---

4. Mass Screening vs High-Risk Screening

---

5. PPV vs NPV

---

6. False Negative vs False Positive

---

ONE-LINERS

1. Screening = "search for unrecognized disease in apparently healthy individuals."
2. Screening differs from periodic health exam as it is cheaper, wider, needs less physician-time.
3. Sensitivity = ability to detect true positives = a/(a+c) × 100.
4. Specificity = ability to detect true negatives = d/(b+d) × 100.
5. High sensitivity = few false negatives; high specificity = few false positives.
6. No test is 100% sensitive AND 100% specific.
7. Sensitivity was introduced by Yerushalmy in the 1940s.
8. SnOut = Sensitive test, Negative result rules Out disease.
9. SpIn = Specific test, Positive result rules In disease.
10. False negative = "false reassurance" - diseased told they are healthy.
11. False positive = healthy person told they are diseased → anxiety and discredits programme.
12. The more prevalent the disease, the higher the PPV.
13. PPV falls as disease prevalence declines.
14. Yield = amount of previously unrecognized disease diagnosed by screening.
15. High-risk screening is most productive type of screening.
16. Multiphasic screening has shown no benefit in reducing morbidity/mortality (RCTs in UK and USA).
17. Lead time = period between screening detection and clinical detection.
18. Case detection = "prescriptive screening" = for benefit of the individual.
19. Control of disease = "prospective screening" = for benefit of others.
20. Observer variation: inter-observer is more common and more serious than intra-observer.
21. Repeatability = consistency of test on repetition = also called reliability/precision/reproducibility.
22. Repeatability depends on: observer variation, biological variation, technical errors.
23. Blood pressure is a poorly reproducible measurement (affected by all 3 factors).
24. Parallel testing → increases sensitivity; serial testing → increases specificity.
25. Syphilis screening: RPR first (sensitive) → FTA-ABS (specific) = serial testing.
26. Cut-off raised → specificity rises, sensitivity falls.
27. Cut-off lowered → sensitivity rises, specificity falls.
28. To increase yield → screen high-prevalence/high-risk populations.
29. Deep burial is irrelevant to screening - (be careful not to mix topics).
30. Evaluation of screening: ideal method = Randomized Controlled Trial (RCT).

---

FILL IN THE BLANKS

1. Screening is defined as the search for unrecognized disease in __________ individuals. (apparently healthy)
2. Screening requires little __________ time. (physician)
3. A screening test is __________ a diagnostic test. (not)
4. Lead time = period between detection by __________ and time it would have been detected clinically. (screening)
5. The 4 uses of screening are case detection, __________, research, and __________. (disease control; evaluation)
6. Case detection is also called "__________ screening". (prescriptive)
7. Control of disease by screening is also called "__________ screening". (prospective)
8. Three types of screening are __________, __________, and __________. (mass; high-risk/selective; multiphasic)
9. High-risk screening is the __________ productive type of screening. (most)
10. Multiphasic screening is application of __________ or more tests in combination to large numbers. (two)
11. Multiphasic screening has shown __________ benefit in reducing morbidity/mortality by RCTs. (no)
12. Criteria for screening are based on two considerations: the __________ and the __________. (disease; test)
13. The disease should have a recognizable __________ or early asymptomatic stage. (latent)
14. Sensitivity = __________ / (a+c) × 100. (a)
15. Specificity = __________ / (b+d) × 100. (d)
16. False negative rate = __________ / (a+c) × 100. (c)
17. False positive rate = __________ / (b+d) × 100. (b)
18. PPV = a / __________ × 100. (a+b)
19. NPV = d / __________ × 100. (c+d)
20. Sensitivity was introduced by __________ in the 1940s. (Yerushalmy)
21. High sensitivity → few __________. (false negatives)
22. High specificity → few __________. (false positives)
23. False negative = "false __________" given to the patient. (reassurance)
24. False positive brings __________ to screening programmes. (discredit)
25. PPV rises as disease __________ increases. (prevalence)
26. PPV falls as disease prevalence __________. (declines)
27. Yield depends on sensitivity, specificity, __________ and participation rate. (prevalence)
28. SnOut = __________ test, Negative result rules Out disease. (Sensitive)
29. SpIn = __________ test, Positive result rules In disease. (Specific)
30. Parallel testing increases __________; serial testing increases __________. (sensitivity; specificity)
31. In serial syphilis testing, RPR is done first (high __________ test). (sensitivity)
32. Repeatability is also called reliability, precision or __________. (reproducibility)
33. Observer variation between different observers = __________ variation. (inter-observer)
34. Observer variation by the same observer = __________ variation. (intra-observer)
35. __________ observer variation is more common and more serious. (Inter-observer)

---

QUICK MEMORY AIDS

The 2×2 Table = ABCD

          Disease +    Disease -
Test +  |    a (TP)  |   b (FP)  |
Test -  |    c (FN)  |   d (TN)  |

• a = A sick person is positive ✓
• b = Being fooled (FP - not sick but positive)
• c = Case missed (FN - sick but negative)
• d = Definitely not sick and negative ✓

Formulas = "a cures, d doesn't"

• Sensitivity → a is in numerator, denominator is a+c (all diseased)
• Specificity → d is in numerator, denominator is b+d (all non-diseased)
• PPV → a in numerator, denominator is a+b (all positives)
• NPV → d in numerator, denominator is c+d (all negatives)

Types of Screening = MHM (Mast High Multi)

• Mass
• High-risk/selective (best)
• Multiphasic (doubtful utility)

Criteria for Disease = "I LENT FEE-B" (9 points)

• Important health problem
• Latent/asymptomatic stage recognizable
• Early history understood
• Not obvious at onset (test can detect pre-symptom)
• Treatment facilities available
• Facilities for diagnosis confirmation
• Effective treatment exists
• Early detection reduces morbidity/mortality
• Benefits exceed risks and costs

Sensitivity vs Specificity Inverse Trade-off:

• Sensitivity ↑ = cut-off ↓ = more positives caught = more false positives
• Specificity ↑ = cut-off ↑ = more negatives caught = more false negatives

---